Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brentuximab Vedotin in Front-line DLBCL
NCT01925612Phase 2Terminated
- Sponsor
- Seagen Inc.
- Start
- Aug 2013
- Primary completion
- May 2017
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of brentuximab vedotin in diffuse large B-cell lymphoma (DLBCL), sponsored by Seagen Inc.. Started Aug 2013; status: terminated.
02
Drugs
brentuximab vedotin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT01925612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01925612.